Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer

  • Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown great results in numerous clinical trials and have improved the clinical outcome for patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer significantly. To date, three CDK4/6 inhibitors are approved by the US Food and Drug Administration (FDA): palbociclib, ribociclib and abemaciclib; the first two compounds are aproved by the European Medicines Agency (EMA) as well. In combination with endocrine therapy, all of them led to significantly improved progression-free survival compared with endocrine therapy alone. The aim of this article is to give an overview of the efficacy data and to describe the CDK4/6 inhibitor-based treatment-associated adverse events, including hematological and nonhematological adverse events. In addition, it describes the corrrect approach to patient monitoring and adverse event mangement and summarizes the current recommendations for dose reductions and dose interruptions regarding the key adverse events, such as neutropenia, diarrhea, QTc prolongation and hepatobiliary toxicity. Accurate patient monitoring and management of the side effects is crucial, as several clinical trials in early breast cancer are in progress and may lead to an additional approval in the neo-/adjuvant setting.

Download full text files

Export metadata

Metadaten
Author:Marc Thill, Marcus Schmidt
URN:urn:nbn:de:hebis:30:3-466956
DOI:https://doi.org/10.1177/1758835918793326
ISSN:1758-8359
ISSN:1758-8340
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/30202447
Parent Title (English):Therapeutic advances in medical oncology
Publisher:Sage
Place of publication:Thousand Oaks, Calif.
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/09/03
Publishing Institution:Universit├Ątsbibliothek Johann Christian Senckenberg
Release Date:2018/09/20
Tag:CDK4/6 inhibitor; abemaciclib; breast cancer; clinical management; palbociclib; ribociclib; toxicity
Volume:10
Page Number:12
First Page:1
Last Page:12
Note:
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
HeBIS-PPN:437863042
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universit├Ątspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0